Valiant LaboratoriesNSE:VALIANTLAB +0.31%51 ROC (Joel Greenblatt) % is 2.52% as of Mar. 2026, which is 85% below its 10-year median of 16.69. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹102.79 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 977 Drug Manufacturers companies, Valiant Laboratories ranks worse than 68.37% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Valiant Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 2.52%.
The historical rank and industry rank for Valiant Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:VALIANTLAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -0.6 Med: 16.69 Max: 77.4
Current: 0.89
During the past 6 years, Valiant Laboratories's highest ROC (Joel Greenblatt) % was 77.40%. The lowest was -0.60%. And the median was 16.69%.
NSE:VALIANTLAB's ROC (Joel Greenblatt) % is ranked worse than 68.37% of 977
companies
in the Drug Manufacturers industry
Industry Median: 11.37
vs NSE:VALIANTLAB: 0.89
Valiant Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Valiant Laboratories ROC (Joel Greenblatt) % Related Terms
Valiant Laboratories ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:VALIANTLAB vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 2.52% mean?
Valiant Laboratories (NSE:VALIANTLAB) has a ROC (Joel Greenblatt) % of 2.52% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Valiant Laboratories and its competitors. This is 85% below median its historical median of 16.69. According to the industry distribution chart, Valiant Laboratories ranks #668 out of 977 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is Valiant Laboratories' ROC (Joel Greenblatt) % too high?
Valiant Laboratories' current ROC (Joel Greenblatt) % of 2.52% is 85% below median its 10-year median of 16.69. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.37. Valiant Laboratories' value of 2.52% is 77.8% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #668 out of 977 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #668 out of 977 companies for ROC (Joel Greenblatt) %. This places Valiant Laboratories in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.37. Valiant Laboratories' value of 2.52% is 77.8% below this benchmark. While the company's 10-year median is 16.69 vs. the industry median of 11.37, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.37, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current ROC (Joel Greenblatt) % of 2.52% is 77.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current ROC (Joel Greenblatt) % is 2.52%, which is 85% below median its own 10-year median of 16.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹102.79, compared to a current price of ₹65.01 — trading 36.8% below its estimated fair value. The current ROC (Joel Greenblatt) % is 2.52%, which is 85% below median its 10-year median of 16.69 and 77.8% below the Drug Manufacturers industry median of 11.37. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current ROC (Joel Greenblatt) % is 2.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹65.01 is trading 36.8% below its estimated GF Value™ of ₹102.79.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
ROC (Joel Greenblatt) %: 2.52% (85% below median its 10-year median of 16.69)
GF Value™: ₹102.79 vs. price of ₹65.01 (36.8% below fair value)
Industry Position: 77.8% below the Drug Manufacturers median (#668 of 977)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
